Compounds > oxepinac
Page last updated: 2024-11-06

oxepinac

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Oxepinac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory and analgesic properties. It is a derivative of naproxen and has been studied for its potential therapeutic benefits in various conditions, including pain and inflammation. Oxepinac is believed to exert its effects by inhibiting the production of prostaglandins, which are inflammatory mediators. The synthesis of oxepinac involves a multi-step process starting from naproxen. Oxepinac has been shown to be effective in reducing pain and inflammation in animal models. However, it has not yet been approved for human use. Further research is needed to evaluate its efficacy and safety in humans.'

oxepinac: non-steroidal anti-inflammatory drug; RN given refers to parent cpd; structure in first source & Negwer, 5th ed, #6399 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID41531
CHEMBL ID312109
SCHEMBL ID106088
MeSH IDM0083916

Synonyms (27)

Synonym
CHEMBL312109 ,
6,11-dihydro-11-oxodibenz(b,e)oxepin-3-acetic acid
6,11-dihydro-11-oxodibenz(b,e)oxepin-3-essigsaure [german]
brn 1320301
oxepinacum [inn-latin]
oxepinaco [inn-spanish]
oxepinac [inn]
oxepinaco [spanish]
6,11-dihydro-11-oxo-dibenz(b,e)oxepin-3-acetic acid
dibenz(b,e)oxepin-3-acetic acid, 6,11-dihydro-11-oxo-
oxepinac
2-(11-oxo-6h-benzo[c][1]benzoxepin-3-yl)acetic acid
(11-oxo-6,11-dihydro-dibenzo[b,e]oxepin-3-yl)-acetic acid
bdbm50022265
oxepinacum
pf3750d8ae ,
6,11-dihydro-11-oxodibenz(b,e)oxepin-3-essigsaure
unii-pf3750d8ae
55689-65-1
oxepinaco
5-18-08-00459 (beilstein handbook reference)
oxepinac [jan]
SCHEMBL106088
DTXSID10204219
di-iso-decylphthalate
Q27286511
2-(11-oxo-6,11-dihydrodibenzo[b,e]oxepin-3-yl)acetic acid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Aldo-keto reductase family 1 member B1Homo sapiens (human)IC50 (µMol)0.33000.00101.191310.0000AID34782
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (15)

Processvia Protein(s)Taxonomy
retinoid metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
epithelial cell maturationAldo-keto reductase family 1 member B1Homo sapiens (human)
renal water homeostasisAldo-keto reductase family 1 member B1Homo sapiens (human)
carbohydrate metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
prostaglandin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
C21-steroid hormone biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
L-ascorbic acid biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
regulation of urine volumeAldo-keto reductase family 1 member B1Homo sapiens (human)
retinol metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
negative regulation of apoptotic processAldo-keto reductase family 1 member B1Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
fructose biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
cellular hyperosmotic salinity responseAldo-keto reductase family 1 member B1Homo sapiens (human)
metanephric collecting duct developmentAldo-keto reductase family 1 member B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
retinal dehydrogenase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member B1Homo sapiens (human)
protein bindingAldo-keto reductase family 1 member B1Homo sapiens (human)
electron transfer activityAldo-keto reductase family 1 member B1Homo sapiens (human)
prostaglandin H2 endoperoxidase reductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
glyceraldehyde oxidoreductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
allyl-alcohol dehydrogenase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
L-glucuronate reductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
glycerol dehydrogenase [NADP+] activityAldo-keto reductase family 1 member B1Homo sapiens (human)
all-trans-retinol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
extracellular spaceAldo-keto reductase family 1 member B1Homo sapiens (human)
nucleoplasmAldo-keto reductase family 1 member B1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B1Homo sapiens (human)
extracellular exosomeAldo-keto reductase family 1 member B1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (23)

Assay IDTitleYearJournalArticle
AID34789In vitro inhibition of rabbit lens aldose reductase at 10e-6 M.1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Antiinflammatory and aldose reductase inhibitory activity of some tricyclic arylacetic acids.
AID1150262Antiinflammatory activity in Wistar albino rat assessed as inhibition of adjuvant-induced arthritis at 0.5 mg/kg, po administered for 14 days prior to adjuvant challenge relative to control1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
6,11-Dihydro-11-oxodibenz [b,e] oxepinacetic acids with potent antiinflammatory activity.
AID1132867Toxicity in po dosed Donryu rat assessed as mortality1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Nonsteroidal antiinflammatory agents. 2. Derivatives/analogues of dibenz[b,e]oxepin-3-acetic acid.
AID107291Analgesic activity in mice by mouse phenylquinone writhing assay relative to aspirin.1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Antiinflammatory and aldose reductase inhibitory activity of some tricyclic arylacetic acids.
AID1150267Antiinflammatory activity in Wistar albino rat assessed as inhibition of adjuvant-induced arthritis at 0.5 mg/kg, po administered for 14 days followed by adjuvant challenge relative to control1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
6,11-Dihydro-11-oxodibenz [b,e] oxepinacetic acids with potent antiinflammatory activity.
AID1132864Therapeutic index, ratio of UD50 for ulcerogenicity in po dosed Donryu rat assessed as gastric lesion to ID50 for antiinflammatory activity in po dosed Donryu rat assessed as inhibition of carrageenan-induced paw edema1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Nonsteroidal antiinflammatory agents. 2. Derivatives/analogues of dibenz[b,e]oxepin-3-acetic acid.
AID1150259Antiinflammatory activity in rat with prolonged phase of inflammation assessed as inhibition of adjuvant-carrageenan-induced paw edema at 2 mg/kg, po relative to control1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
6,11-Dihydro-11-oxodibenz [b,e] oxepinacetic acids with potent antiinflammatory activity.
AID34788In vitro inhibition of rabbit lens aldose reductase at 10e-5 M.1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Antiinflammatory and aldose reductase inhibitory activity of some tricyclic arylacetic acids.
AID1150274Toxicity in po dosed rat assessed as induction of gastric lesion1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
6,11-Dihydro-11-oxodibenz [b,e] oxepinacetic acids with potent antiinflammatory activity.
AID1150271Analgesic activity in carrageenan-treated po dosed rat assessed as concentration required to double pain index of control1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
6,11-Dihydro-11-oxodibenz [b,e] oxepinacetic acids with potent antiinflammatory activity.
AID1150252Antiinflammatory activity in po dosed rat assessed as inhibition of carrageenan-induced paw edema1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
6,11-Dihydro-11-oxodibenz [b,e] oxepinacetic acids with potent antiinflammatory activity.
AID177423Compound was evaluated for the effective dose required for the inhibition of rat carrageenan foot edema (CFE) assay1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and antiinflammatory/analgesic activities of 11H-dibenzo[b, e,][1,4]dioxepinacetic acids.
AID1150275Acute toxicity in po dosed rat after 7 days1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
6,11-Dihydro-11-oxodibenz [b,e] oxepinacetic acids with potent antiinflammatory activity.
AID170138Inhibition of carrageenan-induced inflammation of rat paw relative to phenylbutazone.1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Antiinflammatory and aldose reductase inhibitory activity of some tricyclic arylacetic acids.
AID1150273Potency index, ratio of compound to ketoprofen for analgesic activity in carrageenan-treated po dosed rat assessed as concentration required to double pain index of control1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
6,11-Dihydro-11-oxodibenz [b,e] oxepinacetic acids with potent antiinflammatory activity.
AID1150272Potency index, ratio of compound to indomethacin for analgesic activity in carrageenan-treated po dosed rat assessed as concentration required to double pain index of control1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
6,11-Dihydro-11-oxodibenz [b,e] oxepinacetic acids with potent antiinflammatory activity.
AID1132866Ulcerogenicity in po dosed Donryu rat assessed as gastric lesion1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Nonsteroidal antiinflammatory agents. 2. Derivatives/analogues of dibenz[b,e]oxepin-3-acetic acid.
AID34782In vitro inhibition of rabbit lens aldose reductase.1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Antiinflammatory and aldose reductase inhibitory activity of some tricyclic arylacetic acids.
AID34786In vitro inhibition of rabbit lens aldose reductase at 10e-4 M.1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Antiinflammatory and aldose reductase inhibitory activity of some tricyclic arylacetic acids.
AID1150257Antiinflammatory activity in rat with acute phase of inflammation assessed as inhibition of adjuvant-carrageenan-induced paw edema at 2 mg/kg, po relative to control1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
6,11-Dihydro-11-oxodibenz [b,e] oxepinacetic acids with potent antiinflammatory activity.
AID1132865Antiinflammatory activity in po dosed Donryu rat assessed as inhibition of carrageenan-induced paw edema1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Nonsteroidal antiinflammatory agents. 2. Derivatives/analogues of dibenz[b,e]oxepin-3-acetic acid.
AID1132868Therapeutic index, ratio of LD50 for po dosed Donryu rat assessed as mortality to ID50 for antiinflammatory activity in po dosed Donryu rat assessed as inhibition of carrageenan-induced paw edema1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Nonsteroidal antiinflammatory agents. 2. Derivatives/analogues of dibenz[b,e]oxepin-3-acetic acid.
AID1150270Analgesic activity in po dosed mouse assessed as inhibition of acetic acid-induced writhing1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
6,11-Dihydro-11-oxodibenz [b,e] oxepinacetic acids with potent antiinflammatory activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.50 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
salicylic acid
Scalp: The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL).		1.9610monohydroxybenzoic acidalgal metabolite;
antifungal agent;
antiinfective agent;
EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor;
keratolytic drug;
plant hormone;
plant metabolite
flufenamic acid
Flufenamic Acid: An anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders and administered by mouth and topically. (From Martindale, The Extra Pharmacopoeia, 30th ed, p16). flufenamic acid : An aromatic amino acid consisting of anthranilic acid carrying an N-(trifluoromethyl)phenyl substituent. An analgesic and anti-inflammatory, it is used in rheumatic disorders.		1.9610aromatic amino acid;
organofluorine compound		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
indomethacin
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.		2.8740aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
ketoprofen
Ketoprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis.. ketoprofen : An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2.		2.3620benzophenones;
oxo monocarboxylic acid		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-steroidal anti-inflammatory drug;
xenobiotic
phenylbutazone
Phenylbutazone: A butyl-diphenyl-pyrazolidinedione that has anti-inflammatory, antipyretic, and analgesic activities. It has been used in ANKYLOSING SPONDYLITIS; RHEUMATOID ARTHRITIS; and REACTIVE ARTHRITIS.. phenylbutazone : A member of the class of pyrazolidines that is 1,2-diphenylpyrazolidine-3,5-dione carrying a butyl group at the 4-position.		1.9510pyrazolidinesantirheumatic drug;
EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor;
metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug
zomepirac
zomepirac: RN given refers to parent cpd; structure		1.9610aromatic ketone;
monocarboxylic acid;
monochlorobenzenes;
pyrroles		cardiovascular drug;
non-steroidal anti-inflammatory drug
phenyl acetate
phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.		2.3620benzenes;
phenyl acetates
isoxepac
isoxepac: orally effective non-steroidal anti-inflammatory agent with moderate analgesic & antipyretic activity; structure in first three sources		2.3620dibenzooxazepine
tiopinac
[no description available]		1.9610
sorbinil
sorbinil: aldose reductase inhibitor. sorbinil : An azaspiro compound having a monofluoro-substituted chromane skeleton spiro-linked to an imidazolidinedione ring.		1.9610azaspiro compound;
chromanes;
imidazolidinone;
organofluorine compound;
oxaspiro compound		antioxidant;
EC 1.1.1.21 (aldehyde reductase) inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Anasarca
[description not available]		02.6530
Gastric Ulcer
[description not available]		02.3620
Edema
Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.		02.6530
Stomach Ulcer
Ulceration of the GASTRIC MUCOSA due to contact with GASTRIC JUICE. It is often associated with HELICOBACTER PYLORI infection or consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).		02.3620
Rheumatoid Arthritis
[description not available]		01.9510
Muscle Spasm
[description not available]		01.9510
Arthritis, Rheumatoid
A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.		01.9510
Spasm
An involuntary contraction of a muscle or group of muscles. Spasms may involve SKELETAL MUSCLE or SMOOTH MUSCLE.		01.9510
Hematochezia
The passage of bright red blood from the rectum. The blood may or may not be mixed with formed stool in the form of blood, blood clots, bloody stool or diarrhea.		01.9610
Ache
[description not available]		01.9610
Gastrointestinal Hemorrhage
Bleeding in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM.		01.9610
Pain
An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.		01.9610